

IGCPHARMA

Transforming Alzheimer's Care

NYSE AMERICAN: **IGC**

Date: 2026



The information presented in these slides includes forward-looking statements regarding the business prospects of IGC Pharma, Inc. ("IGC" or the "Company"). These forward-looking statements are based on management's current expectations as of the date of this presentation and are subject to a number of risks and uncertainties, many of which are beyond our control. Forward-looking statements can often be identified by words such as "believes," "expects," "anticipates," "plans," "will," "goal," "may," "intends," "assumes," or similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or implied. These risks and uncertainties include, but are not limited to: clinical trial outcomes, patient recruitment timelines, clinical site performance, management's ability to recruit sites, patients, and monitor clinical trials, regulatory approvals, competition, funding availability, intellectual property protection.

The forward-looking statements are based on assumptions that the Company has made in light of its industry experience and its perceptions of historical trends, current conditions, expected future developments, and other factors believed to be appropriate under the circumstances. However, these assumptions are inherently subject to uncertainty and changes. IGC's actual results may differ materially from those anticipated in these forward-looking statements due to various factors. The forward-looking statements are not guarantees of future performance. Important factors that could cause actual results to differ materially from recent results or those projected in forward-looking statements are included in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent filings on Form 10-Q, which are accessible on the SEC's website (www.sec.gov). The Company undertakes no obligation and expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation.





- ⌂ **IGC is a clinical-stage biopharmaceutical company.**
- ⌂ **IGC Pharma** is listed on NYSE American: [IGC](#)
- ⌂ HQ in Maryland, USA. Website: <https://igcpharma.com/>
- ⌂ This presentation is on IGC-AD1, a patent protected combination therapy currently in a **Phase 2 trial** ([CALMA](#)) for **agitation** in **Alzheimer's dementia**.
- ⌂ CALMA will enroll **146 patients**. 65% Enrolled as of December 2025.
- ⌂ Phase 1 completed, and Phase 2 Interim data (n=26 **patients**) are presented here.
- ⌂ The trial is currently recruiting in USA, Canada and Colombia

- The Problem & Our Solution
- Investment Highlights
- Milestones
- Interim Results



IGCPHARMA

Transforming Alzheimer's Care

Alzheimer's Disease

Individuals World Wide with AD by 2050

>100 million individuals

400 million

At Risk for AD

No cure for AD

"...Every few Seconds, Another Memory Begins to Fade, we are here to slow that clock..."



The Problem: Agitation in Alzheimer's

Agitation: Agitation refers to a range of behaviors, excessive motor activity, verbal aggression, or physical aggression that is severe enough to impair personal relationships, social functioning, and/or daily activities⁽¹⁾.

Agitation starts early in AD and increases in severity as the disease progresses

40-80% of Alzheimer's patients suffer from agitation

Agitation is associated with:

- ⌂ Higher admission rate to assisted living facilities
- ⌂ Higher use of medications
- ⌂ Long-term hospitalization
- ⌂ Higher mortality

The current approved drug takes 6-10 weeks to reduce agitation and comes with a boxed warning.

- ⌂ The unmet need is a safer faster acting medication



Solution - IGC-AD1 Fast acting & Safe

- ✦ A combination medicine that targets agitation quickly and safely.
- ✦ Phase 1 clinical data showed clinical and statistically significant improvements in agitation.
- ✦ Phase 2 interim clinical data shows clinical and statistically significant reduction in agitation as early as 2 weeks.
- ✦ Our objective is to complete a large Phase 2/3 study (N=146) targeting agitation in AD and move the drug towards commercialization.

North America And Europe			
Item	Adoption	Adoption	Adoption
Individuals with AD - TAM	15 million	15 million	15 million
Agitation in AD (76%) - SAM	11 million	11 million	11 million
% adoption of IGC-AD1 SOM	3%	5%	10%
Monthly Price of drug	\$750	\$750	\$750
Estimated annual Revenue	~\$3B	~\$5B	~\$10B



Current Drug: \$1,500/ month (2X – IGC AD1)




Large global market



Accessible at an affordable price

* www.alzheimer-europe.org/ - <https://www.alz.org/> <https://www.hsph.harvard.edu/news/press-releases/alzheimers-international-survey/> <https://www.alzint.org/about/dementia-facts-figures/dementia-statistics>



The study targets completion by
146 participants
>65% enrolled

Multicenter, Double Blind, Randomized, Placebo-Controlled

Objectives:

- Primary: safety and efficacy of IGC-AD1 on agitation in AD at week 6 using the CMAI
- Secondary: Agitation at week 2 using the CMAI
- Exploratory: AD Blood biomarkers (p-tau217/A β 42 ratio, p-tau217, NFL...) CGI, MMSC, ZBI, and other scales

Key Inclusion Criteria:

- Probable AD using the NIA-AA criteria
- Clinically significant agitation(score ≥ 4 in NPI agitation domain)

USA Locations

- ✚ Butler Hospital, Brown University
- ✚ MedStar Franklin Square / Georgetown / Montgomery Medical Centers
- ✚ University of South Florida Department of Psychiatry and Behavioral Neurosciences
- ✚ Dent Neurosciences Research Center
- ✚ Miami Jewish Health
- ✚ BayCare Health System Inc

- ✚ ClinCloud, LLC
- ✚ Global Medical Institutes Florida, LLC
- ✚ Neurostudies Inc.

- ✚ Tandem Intermediate, LLC
- ✚ Tekton Research LLC

- ✚ Integrative Clinical Trials, LLC
- ✚ Ichor Research
Lynn Health Science Institute (LHSI)

- ✚ Senior Adults Specialty Research
- ✚ Dominion Medical Associates, Inc.

Canada


- ✚ Douglas Hospital Research Center, McGill university
- ✚ Hamilton Health Sciences , McMaster University
- ✚ Baycrest Academy, University of Toronto

Puerto Rico

- ✚ University of Puerto Rico
- ✚ SCB Research Center
- ✚ Instituto Sanacoop

Colombia, South America

- ✚ Grupo de Neurociencias de Antioquia, Universidad de Antioquia
- ✚ Psynapsis Salud Mental



* Δ ADJUSTED MEAN OF COHEN MANSFIELD AGITATION INVENTORY (CMAI)

- Compared to published results of Brexpiprazole, IGC-AD1 appears to be faster acting than Brexpiprazole.
- IGC-AD1 demonstrates a large effect size (Cohen’s d = 0.79) and is more strongly distinguished from placebo at week 2 and 6 compared to Brexpiprazole

- Brexpiprazole has limited effect at week 2
- Brexpiprazole starts to show effect at week 6
- Brex Cohen’s d = 0.4, (p=.001) at week 12

* CMAI Least Squared mean change from baseline at EOT comparing active and placebo groups A) IGC-AD1 1ml BID trial (NCT05543681) and Brexpiprazole trial 0.5 to 2 mg flexible doses trial (NCT01922258). * p<0.05, ** p<0.01, b p<0.001; Mixed Model of Repeated Measures. SE: Standard Error; CMAI: Cohen-Mansfield Agitation Inventory.
* This is a not a direct comparison

Grossberg GT, Kohegyi E, Mergel V, et al. Am J Geriatr Psychiatry. 2020;28(4):383-400. doi:10.1016/j.jagp.2019.09.009

Brexpiprazole Trial

- ~6% participants had SAEs
- 5% participants had AEs leading to discontinuation
- 7 deaths reported, 6 in the active group and 1 in placebo

IGC-AD1 Trial to date

- ☞ No SAEs reported up to 6 weeks
- ☞ No AEs leading to discontinuation
- ☞ No deaths

1. Data obtained from: Otsuka Pharmaceutical Company. (2023, April). BREXPIPRAZOLE FOR THE TREATMENT OF AGITATION ASSOCIATED WITH ALZHEIMER'S DEMENTIA SPONSOR BRIEFING DOCUMENT. <https://www.fda.gov/media/167068/download>

Disease Modifying Potential



IGCPHARMA

Transforming Alzheimer's Care

IGC-AD1: Preclinical Evidence Supporting Disease-Modifying Potential in Humans

- Decreases $A\beta_{40}$ production and aggregation in cell models, implicates amyloid pathway modulation.¹
- Reduces pTau and total Tau in transgenic mouse models.²
- Enhances mitochondrial function and restores respiratory capacity in AD models, supports neuronal survival and synaptic health.¹⁻³

- Improves spatial memory in APP/PS1 mice, correlating with potential cognitive benefit in human AD patients.⁴
- Crosses the blood-brain barrier (BBB), enabling direct central nervous system activity.²
- Supports long-term neuroprotection through modulation of GSK-3 β , a kinase involved in tau phosphorylation and apoptosis.²

These mechanistic effects provide a rationale for future clinical trials evaluating IGC-AD1 as a disease-modifying therapy with target clinical biomarker, for example, reduction in CSF pTau181 or pTau217, a validated surrogate of Alzheimer's progression

1. J. Alzheimer's disease 2014, 42, 973-984; 2. Biomolecules. 2023;13(2):232 3. J. Pineal. Res. 2011, 51, 75-86; 4. Int. J. Mol. Sci. 2022, 23, 2757;

- Our Pipeline
- Intellectual Property
- Team












IGCPHARMA

Transforming Alzheimer's Care

Our Pipeline



Target	Description	Patent Applications	US Patents Granted	Foreign Patents Granted
IGC-AD1	 Composition & Method for treating CNS Disorders	1	2	-
IGC-AD1	 Composition & Method for treating CNS Disorders	11	1	1
TGR-63	 Naphthalene Monoimide Derivatives with ability to impact A β protein build-up	6	-	-
IGC-1C	 Naphthalene Monoimide Derivatives with ability to impact Tau aggregation and neurofibrillary tangle formation	5	-	-
IGC-M3	 Naphthalene Monoimide Derivatives with ability to impact A β plaque buildup and neurofibrillary tangle formation	4	-	-
Cancer (Naphthalene Dimides)	 Naphthalene diimide Derivatives with ability to self-assemble molecular interactions for biological and nonbiological systems	12	1	1
IGC-LMP	 Composition, Synthesis & Medical use of Hybrid Molecule	1	-	-
Epilepsy I	 Composition & Method for treating Seizures in humans & Cats/Dogs	-	2	-
Eating Disorders	 Natural formulation with Cyproheptadine for treating Cachexia & Eating Disorders	-	1	-
Stuttering & Tourette Syndrome	 Formulation for Treating Stuttering & Symptoms of Tourette Syndrome	1	-	-
Pain	 Formulation containing Cobalamin and method for pain management	1	2	2

We have 30 active patent applications which are distributed among the US, Canada, Europe, Colombia, India, Brazil, Japan and Hong Kong and 13 granted patents in US, Canada, Europe and Mexico.

30

9

4

 In-house patents / applications

 Patents / applications acquired through exclusive license agreements

Protected Intellectual Property

Executive management



Ram Mukunda,
Biomedical Engineer
CEO



Claudia Grimaldi
Psychologist, MBA
VP, PFO

Independent Board



Richard Prins
Chairman



James Moran
Former Congressman



Terry Lierman
Human Virology (IHV)

Corporate Advisory Board



Terry McAuliffe
Former Governor of Virginia



Howard Gutman
Ambassador to Belgium (rtd.)

Chemistry and Pharmaceutical Sciences



Prof. Joseph Fortunak,
PhD
Professor
Chemistry and
Pharmaceutical
Sciences



Prof. Chuanhai Cao,
PhD
Professor of
Pharmaceutical
Sciences



Prof. James Saunders,
PhD
Ret.
Professor,
Molecular
Biology



Psychiatry, Neurology and AI



Prof. Elliot Hong,
MD
Professor
Psychiatrist



Prof. Jeffrey Cummings,
MD, ScD, Chair of the
ACTC
Neuropsychiatric
Symptoms
Committee



Prof. Pablo Arbelaez,
PhD
Professor
Biomedical
Engineering



Join Us in The Fight to Conquer Alzheimer's



IGCPHARMA

www.igcpharma.com

NYSE AMERICAN: **IGC**

Thank you



Ram Mukunda

ram@igcpharma.com



Claudia Grimaldi

cgrimaldi@igcpharma.com